Chemiluminescent probe targeting A beta oligomer as well as preparation method and application of chemiluminescent probe
By developing chemiluminescent probes targeting Aβ oligomers and using chemical excitation to promote selective oxygenation of Aβ proteins, the problem of early diagnosis and inhibition of Aβ oligomers in Alzheimer's disease has been solved, achieving high sensitivity detection and potential therapeutic effects.
CN119684334AActive Publication Date: 2025-03-25CHINA PHARM UNIV
4 Cites 2 Cited by
Patent Information
- Application Number
- CN202411858925.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-12-13
- Filing Date
- 2024-12-17
- Publication Date
- 2025-03-25
- Estimated Expiration
- 2044-12-17
AI Technical Summary
Technical Problem
The prior art is difficult to effectively diagnose and inhibit the early formation and toxic effects of Aβ oligomers in Alzheimer's disease, and there is a lack of efficient and specific Aβ oligomer inhibitors.
Method used
A chemiluminescent probe targeting Aβ oligomers was developed, using boron difluoride structure and imidazolopyrazine backbone to promote selective oxygenation of Aβ proteins and neutralize the toxicity of Aβ oligomers through chemical excitation.
Benefits of technology
High sensitivity detection and imaging of Aβ oligomers have potential therapeutic potential, can inhibit Aβ aggregation and reduce its toxic effects, providing a new treatment method for Alzheimer's disease.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses a chemiluminescent probe of a targeted A beta oligomer as well as a preparation method and application of the chemiluminescent probe. The structural general formula of the chemiluminescent probe of the targeted A beta oligomer is shown as I in the specification. According to the present invention, the chemiluminescence probe capable of specifically targeting the A beta oligomer is successfully constructed for the first time so as to achieve the early diagnosis and treatment of AD; an additional light source is not needed, and background signals caused by exciting light can be effectively reduced, so that the detection sensitivity is higher. The chemiluminescent probe targeting the A beta oligomer can promote selective oxygenation of beta amyloid protein through chemical excitation and neutralize toxicity of the A beta oligomer, has certain treatment potential and is expected to be developed into an effective method for treating amyloidosis. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art